The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.2M Compounds and 9.3K Targets. Of those, 1,359K data for 631K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

89 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Influence of chain length on the activity of tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4).EBI
University of Bergen
Synthesis and evaluation of 2,5 and 2,6 pyridine-based CXCR4 inhibitors.EBI
Georgia State University
Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists.EBI
Universit£
Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists.EBI
Second University of Naples
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.EBI
Shandong University
Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.EBI
Shandong University
Exploration of labeling by near infrared dyes of the polyproline linker for bivalent-type CXCR4 ligands.EBI
Tokyo Medical and Dental University
Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening.EBI
National Health Research Institutes
Discovery of novel N-aryl piperazine CXCR4 antagonists.EBI
Emory Institute For Drug Development
Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase.EBI
Emory University
Design, synthesis, and biological evaluation of scaffold-based tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4).EBI
Uit The Arctic University of Norway
Development of novel CXC chemokine receptor 7 (CXCR7) ligands: selectivity switch from CXCR4 antagonists with a cyclic pentapeptide scaffold.EBI
Kyoto University
Toward fluorescent probes for G-protein-coupled receptors (GPCRs).EBI
Shandong University
Discovery of tetrahydroisoquinoline-based CXCR4 antagonists.EBI
Emory University
Improved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infection.EBI
Montana State University
Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.EBI
Kyoto University
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.EBI
Universite£
Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in Vivo.EBI
TBA
Rational design of conformationally constrained cyclopentapeptide antagonists for C-x-C chemokine receptor 4 (CXCR4).EBI
University of Troms£
Chemokine receptor antagonists.EBI
National Heart and Lung Institute
Noncyclam tetraamines inhibit CXC chemokine receptor type 4 and target glioma-initiating cells.EBI
Universitat Ramon Llull
Potent CXCR4 antagonists containing amidine type Peptide bond isosteres.EBI
TBA
Structure-activity relationship study of a CXC chemokine receptor type 4 antagonist, FC131, using a series of alkene dipeptide isosteres.EBI
Kyoto University
Agonists for the Chemokine Receptor CXCR4.EBI
TBA
Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.EBI
Ono Pharmaceutical
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.EBI
Anormed
Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.EBI
Kyoto University
Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions.EBI
Pharmadesign
Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4.EBI
Technische Universit£T M£Nchen
Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.EBI
Ono Pharmaceutical
Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity.EBI
Emory University
Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.EBI
Genzyme
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.EBI
National Institute of Infectious Diseases
Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication.EBI
Genzyme
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.EBI
Tokyo Medical and Dental University
Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist.EBI
Glaxosmithkline
Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity.EBI
Glaxosmithkline
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.EBI
Genzyme
Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents.EBI
Glaxosmithkline
Spiropiperidine CCR5 antagonists.EBI
Roche Palo Alto
Identification of a new class of small molecule C5a receptor antagonists.EBI
Wyeth Research
64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.EBI
National Institute of Biomedical Imaging and Bioengineering
Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.EBI
Novartis Institutes For Biomedical Research
Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.EBI
Roche Palo Alto
Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach.EBI
Kyoto University
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.EBI
Université
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.EBI
University of Copenhagen
Discovery of small molecule CXCR4 antagonists.EBI
Emory University
Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities.EBI
Kyoto University
A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist.EBI
Tsinghua University
Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds.EBI
Kyoto University
Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131.EBI
Kyoto University
Amino-Heterocycle Tetrahydroisoquinoline CXCR4 Antagonists with Improved ADME Profiles via Late-Stage Buchwald Couplings.EBI
Emory University
Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonists.EBI
University of Michigan
Design, synthesis, and evaluation of pyrrolidine based CXCR4 antagonists with in vivo anti-tumor metastatic activity.EBI
Soochow University
Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry.EBI
Virginia Commonwealth University
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.EBI
University of Florida
Structural optimization of aminopyrimidine-based CXCR4 antagonists.EBI
Soochow University
Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239.EBI
Idorsia Pharmaceuticals
Design and synthesis of a bivalent probe targeting the putative mu opioid receptor and chemokine receptor CXCR4 heterodimer.EBI
Virginia Commonwealth University
Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety.EBI
Kyoto University
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.EBI
Merck Research Laboratories
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.EBI
Merck Research Laboratories
Discovery of Diphenylacetamides as CXCR7 Inhibitors with Novel ?-Arrestin Antagonist Activity.EBI
Pfizer
Discovery of small molecule antagonists of chemokine receptor CXCR6 that arrest tumor growth in SK-HEP-1 mouse xenografts as a model of hepatocellular carcinoma.EBI
Sanford Burnham Prebys Medical Discovery Institute
Design, synthesis, and biological characterization of novel PEG-linked dimeric modulators for CXCR4.EBI
Upstate Medical University
High affinity CXCR4 inhibitors generated by linking low affinity peptides.EBI
University of California San Diego
Tetrahydroisoquinoline CXCR4 Antagonists Adopt a Hybrid Binding Mode within the Peptide Subpocket of the CXCR4 Receptor.EBI
Emory University
Structure-based exploration and pharmacological evaluation of N-substituted piperidin-4-yl-methanamine CXCR4 chemokine receptor antagonists.EBI
Griffin Discoveries
Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands.EBI
Tokyo Medical and Dental University (Tmdu)
The discovery and optimization of a series of 2-aminobenzoxazole derivatives as ChemR23 inhibitors.EBI
Kyowa Kirin
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.EBI
Glaxosmithkline
HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.EBI
University of Osnabr£Ck
The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential.EBI
Central South University
Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists.EBI
Soochow University
Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties.EBI
Emory University
Insight into structural requirements for selective and/or dual CXCR3 and CXCR4 allosteric modulators.EBI
University of Ljubljana
Discovery of EBI
Emory University
Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains.EBI
Emory University
Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists.EBI
Emory University
An update on small molecules targeting CXCR4 as starting points for the development of anti-cancer therapeutics.EBI
University of Calabria
Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties.EBI
Emory University
Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis.EBI
Pfizer
Structure-Activity Relationship Study of Cyclic Pentapeptide Ligands for Atypical Chemokine Receptor 3 (ACKR3).EBI
Kyoto University
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.EBI
Gsk Pharmaceuticals R & D
Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist.EBI
University of Campania
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.EBI
National Health Research Institutes
Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)-Ligand Interactions on Living Cancer Cells.EBI
Universit£